Targeting synovial fibroblast proliferation in rheumatoid arthritis (TRAFIC): an open-label, dose-finding, phase 1b trial

BACKGROUND: Current rheumatoid arthritis therapies target immune inflammation and are subject to ceiling effects. Seliciclib is an orally available cyclin-dependent kinase inhibitor that suppresses proliferation of synovial fibroblasts—cells not yet targeted in rheumatoid arthritis. Part 1 of this p...

Descripción completa

Detalles Bibliográficos
Autores principales: Pratt, Arthur G, Siebert, Stefan, Cole, Michael, Stocken, Deborah D, Yap, Christina, Kelly, Stephen, Shaikh, Muddassir, Cranston, Amy, Morton, Miranda, Walker, Jenn, Frame, Sheelagh, Ng, Wan-Fai, Buckley, Christopher D, McInnes, Iain B, Filer, Andrew, Isaacs, John D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8062952/
https://www.ncbi.nlm.nih.gov/pubmed/33928262
http://dx.doi.org/10.1016/S2665-9913(21)00061-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8062952/
https://www.ncbi.nlm.nih.gov/pubmed/33928262
http://dx.doi.org/10.1016/S2665-9913(21)00061-8

Ejemplares similares